Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.175
-0.055-0.60%
Volume:27.83M
Turnover:257.44M
Market Cap:105.71B
PE:23.15
High:9.375
Open:9.330
Low:9.130
Close:9.230
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.74
T/O Rate:0.24%
Dividend:0.29
Dividend Rate:3.16%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.41
PE(LYR):23.15
PS:2.89

Loading ...

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20

Movement Alert|CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus
·
Jul 20

CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 17

CSPC Pharmaceutical’s Trastuzumab Envedotin NDA Accepted by China’s NMPA

Bulletin Express
·
Jul 17

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17

Movement Alert|CSPC Pharmaceutical Falls 3.02% in Regular Trading, Trading at HKD 8.22

Market Focus
·
Jul 17

CSPC Pharma Begins Two Drug Trials in China

MT Newswires Live
·
Jul 16

CSPC PHARMA Initiates Phase II Trial in China for Novel Sirolimus Formulation in Rare Vascular Tumor

Stock News
·
Jul 16

CSPC PHARMA's Phase III Trial for SYS 6043 in Platinum-Resistant Gynecologic Cancers Commences at First Chinese Site

Stock News
·
Jul 16

CSPC Pharmaceutical Initiates China Phase II Trial of Albumin-bound Sirolimus Injection for Epithelioid Haemangioendothelioma

Reuters
·
Jul 16

CSPC Pharmaceutical Initiates China Phase III Trial of Sys6043 in Platinum-resistant Ovarian Cancer

Reuters
·
Jul 16

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong

Dow Jones
·
Jul 16

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation

Market Focus
·
Jul 16

CSPC Pharmaceutical Group Stock Rises 3.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 15

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer

Market Focus
·
Jul 15

CSPC Pharma’s Albumin-Bound Docetaxel and Anbenitamab Secure China Breakthrough Therapy Status for First-Line HER2-Positive Breast Cancer

Bulletin Express
·
Jul 14

Mutual Fund Boosts Stake in Pharmaceutical Giant with Multi-Million Dollar Purchase

Stock News
·
Jul 14

CSPC Says China Regulator Grants Breakthrough Therapy Designation for Her2-positive Breast Cancer Combo

Reuters
·
Jul 14